David R. Holtgrave
PhD, University of Illinois, 1988
David Holtgrave, PhD currently serves as the Senior Associate Director of the White House Office of National Drug Control Policy (where his portfolio spans public health, prevention, and translational research aspects of substance use policy). He is also appointed as Adjunct Professor with the Department of Health, Behavior and Society at Johns Hopkins Bloomberg School of Public Health (the department he chaired from 2005 to 2018 when employed full time at Hopkins). From 2018 to 2022, he was he Dean and SUNY Empire Innovation Professor at the School of Public Health, University at Albany, State University of New York; in 2019 he was inducted into the SUNY Distinguished Academy as a Distinguished Professor.
Dr. Holtgrave's research has focused heavily on the effectiveness and cost-effectiveness of a variety of HIV prevention and care interventions (including the provision of housing as a structural HIV/AIDS intervention), and the relationship of the findings of these studies to HIV prevention policy making. His scholarly works include over 325 professional publications. He has served on an Institute of Medicine panel charged with recommending methods to improve the public financing and delivery of HIV care in the United States. Dr. Holtgrave has also previously served as the Director of the Division of HIV/AIDS Prevention -- Intervention Research & Support at the US Federal Centers for Disease Control and Prevention (CDC). During President Barack Obama's Administration, Dr. Holtgrave served as a member and then Vice-Chair of the Presidential Advisory Council on HIV/AIDS (PACHA).
Most recently, Dr. Holtgrave worked intensively on COVID-19 projects conducted in partnership with the New York State Department of Health. This work was focused on COVID-19 treatment, prevention, epidemiology, and the addressing of racial and ethnic health disparities.